The global novel coronavirus is rampant, and ventilators have become a “lifesaver”. Ventiators are mainly used in critical medicine, home care and emergency medicine as well as anesthesiology. The barriers to ventilator production and registration are high. The transformation of ventilator production needs to break through the barriers of raw material supply, component assembly and registration certification, and the global ventilator production cannot be greatly improved in the short term.In the global ventilator, the invasive ventilator is mainly supplied by foreign brands. Domestic brands are also rising in recent years.Mindray, Yi’an, Pubo and other production enterprises, have contributed their own strength to the domestic grass-roots level, but also to provide cost-effective ventilators for overseas countries.
Fighting the epidemic at home and abroad, the ventilator gap is huge.According to estimates that in the epidemic, China’s total demand for ventilators is about 32,000 ventilators, of which Hubei province needs 33,000 beds in critical wards, 15,000 beds in critical wards, a total of 7,514 invasive ventilators and 23,000 non-invasive ventilators. Outside of Hubei province, 2,028 critical care ward beds and 936 beds in the critical care wards should be built, and a total of 468 invasive ventilators and 1,435 non-invasive ventilators are needed. It is estimated that the global stock of ventilators is about 430,000 except for China, and at least 1.33 million foreign ventilators are needed abroad to cope with the epidemic, with a gap of 900,000. There are a total of 21 invasive ventilator manufacturers in China, 8 of which their main products have obtained mandatory CE certification from the EU, accounting for about 1 / fifth of the global production capacity. In the huge global gap, providing sufficient ventilators, stabilized the market.
The demand for ventilators is not a short-term transient of the epidemic, but a long-term existence, and the demand for ventilators will continue to grow. In 2016, global ventilator production was about 6.6 million units, with a compound growth rate of 7.2%.In 2018, the annual growth rate of medical ventilators in China was about 15%.There are some gaps between China’s ventilators per capita compared with developed countries in Europe and the United States.After the epidemic, China’s ICU construction will be gradually implemented in place. In addition to ICU departments, other departments of secondary and above hospitals, such as respiratory medicine, anesthesiology, and emergency departments, also have new demand for ventilator. Meanwhile, it is expected that the new demand of primary medical institutions exceeds 20,000 units in the five centers in the next 2-3 years. Domestic ventilators, in terms of performance, are at the international frontier level, such as Yuyue Medical and Ruimin ventilators, have received EUA certificates issued by the FDA, which is enough to prove that the technological strength level is reliable.
In the face of uncertain risks in the progress of the epidemic; risks of overseas macro environment changes; raw material supply risks, domestic ventilators, provide a strong guarantee for the Chinese people, and make the world have “life-saving machines”.
Post time: Dec-01-2021
